Zacks Investment Research on MSN3 天
DXCM Stock Falls as FDA Warnings Raise Concern for 15-Day G7 ApprovalDexCom DXCM is facing regulatory scrutiny following a warning letter recently posted by the FDA. This could affect the ...
Dexcom’s investigational 15-day continuous glucose monitor has a lower mean absolute relative difference than the current ...
A company spokesperson said Dexcom plans to resolve the agency's concerns but stated no design changes were made to its ...
Dexcom made a significant design change to a component used in its sensors and did not adequately validate the change, ...
6 天on MSN
In a new study in the journal Diabetes Technology & Therapeutics (DTT), investigators evaluated the accuracy of the 15.5-day ...
Investing.com — 周二，花旗重申了对DexCom (NASDAQ: DXCM )的买入评级和104.00美元的目标价，此举是在美国食品药品监督管理局 (FDA)公开发布警告信之后。这封最初于2025年3月4日发送的信函详细列出了去年在DexCom位于加利福尼亚州和亚利桑那州的设施检查中发现的违规行为。FDA指出，G6和G7连续血糖监测系统 ...
The agency cited quality issues at facilities testing Dexcom’s G6 and G7 monitors, including inadequate validation and risk ...
DexCom plans to launch its 15-day G7 sensor in the second half of 2025, pending FDA approval. A longer wear time may boost ...
At the conference, first-ever accuracy and performance data will be presented for Dexcom’s upcoming G7 15 Day system,1 ...
Jake Leach caught up with MedTech Dive during the ATTD conference to discuss new data on the company’s glucose monitors and ...
The Joseph P. Addabbo Family Health Center (JPAFHC) in Southeast Queens is making significant strides in diabetes care in New ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈